NCT04052659View on ClinicalTrials.gov

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

Sintilimab

200 mg IV, every 3 weeks, d1

DRUG

Chidamide

30 mg PO, 2 times every week, d1 and d4

DRUG

Azacidine

100 mg SC, every 3 weeks, d1 to d7

Trial Locations (1)

100000

Beijing, Beijing

All Listed Sponsors
lead

Peking University

OTHER